Review of health risks of low testosterone and testosterone administration

摘要

Hypogonadism is prevalent in older men and testosterone replacement therapy(TRT)for older hypogonadal men is a promising therapy.However,a number of important clinical concerns over TRT safety remain unsolved due to a lack of large-scale randomized clinical trials directly comparing the health risks of untreated hypogonadism vs long-term use of TRT.Meta-analyses of clinical trials of TRT as of 2010 have identified three major adverse events resulting from TRT:polycythemia,an increase in prostate-related events,and a slight reduction in serum high-density lipoprotein cholesterol.There are other purported health risks but their incidence can be neither confirmed nor denied based on the small number of subjects that have been studied to date.Furthermore,subsequent literature is equivocal with regard to the safety and utility of TRT and this topic has been subject to contentious debate.Since January 2014,the United States Food and Drug Administration has released two official announcements regarding the safety of TRT and clinical monitoring the risks in TRT users.Additionally,the health risks related to the clinical presentation of low or declining testosterone levels not been resolved in the current literature.Because TRT is prescribed in the context of putative risks resulting from reduced testosterone levels,we reviewed the epidemiology and reported risks of low testosterone levels.We also highlight the current information about TRT utilization,the risks most often claimed to be associated with TRT,and current or emerging alternatives to TRT.